Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 immunogenicity comparison of an E. coli-produced 9-valent HPV vaccine versus Gardasil 9 in healthy women aged 18-26 years
CTR20210365Phase 3Active
- Sponsor
- Xiamen Wantai Canghai Biotechnology Co., Ltd.
- Start
- Mar 2021
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection, Cervical Cancer (CC), anogenital warts, sponsored by Xiamen Wantai Canghai Biotechnology Co., Ltd.. Started Mar 2021; status: active.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)anogenital warts
Beyond the preview
Go deeper on CTR20210365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20210365.